Atlas Trials

Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT07529613 · COMPLETED

Trial details

NCT number
NCT07529613
Sponsor
National Cancer Center Hospital East
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Start date
2023-12-20
Primary completion
2025-12-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.